TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3087915

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (30 or 50 micrograms ethinyl oestradiol and 150 micrograms levonorgestrel)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Depo-medroxyprogesterone acetate (DMPA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral contraceptive pills
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (middle-income reference group)
Number of subjects: 0
Study: 29863964

Group type: EXPERIMENTAL
Intervention: Male targets with anorexia nervosa (AN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Female targets with anorexia nervosa (AN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Male targets with bulimia nervosa (BN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Female targets with bulimia nervosa (BN)
Number of subjects: 0
Study: 29438547

Group type: EXPERIMENTAL
Intervention: Online training for general practitioners (GPs) and an information booklet for parents
Number of subjects: 1009

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1009

Group type: EXPERIMENTAL
Intervention: Online training for GPs and an information booklet for parents
Number of subjects: 1009
Study: 27619760

Group type: EXPERIMENTAL
Intervention: 12-session school nurse-delivered cognitive-behavioral counseling intervention plus school-based after school exercise program
Number of subjects: 126

Group type: COMPARATOR
Intervention: 12-session nurse contact with weight management information (control)
Number of subjects: 126
Study: 25644388

Group type: EXPERIMENTAL
Intervention: Melatonin (2 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Able-bodied subjects (no intervention)
Number of subjects: 12
Study: 23625063

Group type: EXPERIMENTAL
Intervention: docetaxel, cisplatin plus 5-FU (DCF)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: cisplatin plus 5-FU with chemoradiotherapy (CF-RT)
Number of subjects: 501

Group type: COMPARATOR
Intervention: cisplatin plus 5-FU (CF)
Number of subjects: 501
Study: 20655766

Group type: EXPERIMENTAL
Intervention: Intra-articular corticosteroid injection (accuracy identified by fluoroscopy)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Intra-articular corticosteroid injection (accuracy identified by palpation)
Number of subjects: 103
Study: 18173610

Group type: EXPERIMENTAL
Intervention: Zycure (0.005% solasodine glycosides)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 94
Study: 16723194

Group type: COMPARATOR
Intervention: 0 microg/kg THC (placebo)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 250 microg/kg THC
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 500 microg/kg THC
Number of subjects: 20
Study: 14573318

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Antidepressant-free patients
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Antidepressant-treated patients
Number of subjects: 26
Study: 10680784

Group type: EXPERIMENTAL
Intervention: Lidocaine (5 mg/kg IV over 30 minutes)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 16
Study: 9292253

Group type: EXPERIMENTAL
Intervention: Various treatment options that block calcium channels or inhibit the sodium-mediated calcium transporter to prevent axonal damage.
Number of subjects: 0
Study: 8245335

Group type: EXPERIMENTAL
Intervention: 6-month exercise training program (n = 49)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (n = 46)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Both groups (control and training)
Number of subjects: 95
Study: 3535364

Group type: EXPERIMENTAL
Intervention: Intravenous oxytocin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intracervical PGE2‐gel followed by intravenous oxytocin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intracervical PGE2‐gel twice with a 12‐hour interval
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intracervical placebo gel twice with 12‐hour interval
Number of subjects: 100
Study: 29166130

Group type: EXPERIMENTAL
Intervention: JetPeel-assisted topical minoxidil
Number of subjects: 30

Group type: COMPARATOR
Intervention: Topical minoxidil monotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 30
Study: 27190009

Group type: EXPERIMENTAL
Intervention: Rasagiline
Number of subjects: 692

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 692
Study: 25793947

Group type: EXPERIMENTAL
Intervention: Sonic toothbrush
Number of subjects: 40

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 40
Study: 22075447

Group type: EXPERIMENTAL
Intervention: Enhanced education (one education session, plus 11 sessions of group education, individual discussions, and educational plays over six months)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Standard education (one education session and 5 follow up visits)
Number of subjects: 204
Study: 20375907

Group type: EXPERIMENTAL
Intervention: Experimental treatments (BP-lowering agents)
Number of subjects: 221024

Group type: EXPERIMENTAL
Intervention: For each 5-mmHg reduction in SBP
Number of subjects: 221024

Group type: EXPERIMENTAL
Intervention: For each 2-mmHg reduction in DBP
Number of subjects: 221024

Group type: EXPERIMENTAL
Intervention: Different BP reduction of at least 4.6 mmHg in SBP or at least 2.2 mmHg in DBP
Number of subjects: 221024
Study: 17985242

Group type: EXPERIMENTAL
Intervention: Intravenous pantoprazole 80 mg loading dose over 5 min, followed by 8 mg/h intravenous infusion for 72 h, then 40 mg orally once a day for 4 days.
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group received 40 mg pantoprazole intravenously once a day for 72 h, then orally once a day for 4 days.
Number of subjects: 6
Study: 16021478

Group type: EXPERIMENTAL
Intervention: Acupuncture plus antiemetic medication
Number of subjects: 11

Group type: COMPARATOR
Intervention: Anti-emetic medication alone
Number of subjects: 11
Study: 12667379

Group type: EXPERIMENTAL
Intervention: Omeprazole Amoxicillin Clarythromycin (OAC) triple therapy
Number of subjects: 552

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 552
Study: 10894441

Group type: EXPERIMENTAL
Intervention: COER-verapamil
Number of subjects: 1055

Group type: EXPERIMENTAL
Intervention: Amlodipine/Atenolol
Number of subjects: 1055

Group type: EXPERIMENTAL
Intervention: Amlodipine (monotherapy)
Number of subjects: 1055

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1055

Group type: COMPARATOR
Intervention: Nifedipine GITS
Number of subjects: 1055
Study: 8733877

Group type: EXPERIMENTAL
Intervention: iv metoclopramide (MCP) at 30 micrograms/kg/h over 48 h
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Fasting for 56 h
Number of subjects: 11

Group type: COMPARATOR
Intervention: Baseline (ad libitum food)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Fasting for 56 h + iv MCP during the final 48 h
Number of subjects: 11
Study: 1706531

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (HES 40/0.5)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Lactated Ringer solution (LRS)
Number of subjects: 55
Study: 6293715

Group type: EXPERIMENTAL
Intervention: Cefotaxime (20 mg/kg every six hours)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Gentamicin (1 mg/kg every eight hours) plus Clindamycin (5 mg/kg every six hours)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Gentamicin plus Clindamycin
Number of subjects: 98
Study: 30928863

Group type: EXPERIMENTAL
Intervention: 100 mg quetiapine daily for 8 weeks
Number of subjects: 60
Study: 28483885

Group type: EXPERIMENTAL
Intervention: Internet-based vestibular rehabilitation program (Balance Retraining)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Usual primary care
Number of subjects: 296
Study: 25925036

Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block (ISPB) with 20 mL 0.25% bupivacaine
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Intra-articular (IA) administration with 20 mL 0.25% bupivacaine
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (no block performed)
Number of subjects: 3
Study: 23106905

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAT; aspirin and prasugrel)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Triple antiplatelet therapy (TAT; aspirin, clopidogrel, cilostazol)
Number of subjects: 40
Study: 21798863

Group type: EXPERIMENTAL
Intervention: 2 × 25 g/day whey protein (PRO)
Number of subjects: 31

Group type: COMPARATOR
Intervention: maltodextrin (CARB)
Number of subjects: 31
Study: 19326422

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (400 microg) combined with intravenous patient-controlled analgesia (IV-PCA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia (IV-PCA) alone
Number of subjects: 40
Study: 16964364

Group type: EXPERIMENTAL
Intervention: AsthmaCritic (intervention group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 40
Study: 15118182

Group type: COMPARATOR
Intervention: US patients
Number of subjects: 1604

Group type: COMPARATOR
Intervention: Canadian patients
Number of subjects: 1604
Study: 11722037

Group type: EXPERIMENTAL
Intervention: Self-managed anticoagulation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 100
Study: 9394314

Group type: EXPERIMENTAL
Intervention: Sulodexide (600 lipoproteinlipase releasing units by i.m. route, 5 days/week for 3 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (matching i.m. placebo, 5 days/week for 3 weeks)
Number of subjects: 36
Study: 8788011

Group type: EXPERIMENTAL
Intervention: 65% random sample of 648 individuals
Number of subjects: 1000

Group type: COMPARATOR
Intervention: 65% enriched sample with oversampling of individuals with high levels of Q1
Number of subjects: 1000
Study: 2365900

Group type: EXPERIMENTAL
Intervention: Brief cognitive psychotherapy
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Brief behavioral psychotherapy
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Brief psychodynamic psychotherapy
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Posttreatment depression-free patients
Number of subjects: 91
Study: 432541

Group type: EXPERIMENTAL
Intervention: Brush cytology
Number of subjects: 195

Group type: COMPARATOR
Intervention: Endoscopic biopsy
Number of subjects: 195
Study: 30985829

Group type: EXPERIMENTAL
Intervention: Paliperidone
Number of subjects: 0
Study: 28844213

Group type: EXPERIMENTAL
Intervention: R. ribes syrup
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo syrup
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 150
Study: 24596359

Group type: EXPERIMENTAL
Intervention: Tailored exercise intervention
Number of subjects: 25
Study: 21749526

Group type: EXPERIMENTAL
Intervention: Direct buprenorphine/naloxone (BNX) induction
Number of subjects: 187

Group type: COMPARATOR
Intervention: Indirect buprenorphine (BPN)‐to‐BNX induction
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Both groups (direct and indirect induction)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Direct induction
Number of subjects: 187

Group type: COMPARATOR
Intervention: Indirect induction
Number of subjects: 187
Study: 20237186

Group type: EXPERIMENTAL
Intervention: Palmar fixed‐angle plating (n=50)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Mixed pinning (n=53)
Number of subjects: 103
Study: 17939093

Group type: EXPERIMENTAL
Intervention: Ceramic-Ceramic bearing
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Ceramic-Polyethylene bearing
Number of subjects: 66

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 66
Study: 15823788

Group type: EXPERIMENTAL
Intervention: Home-based exercise program (16 weeks, 3 times per week of 30 min of moderate intensity exercise)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Number of subjects: 69

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 69
Study: 12521274

Group type: EXPERIMENTAL
Intervention: Nasal Continuous Positive Airway Pressure (NCPAP)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Oxygen mask treatment
Number of subjects: 37
Study: 9312762

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CTX)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Prednisone (PRE)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Non-steroidal anti-inflammatory drugs (NSAID)
Number of subjects: 150
Study: 8339132

Group type: EXPERIMENTAL
Intervention: 100 mg/day of slow release diclofenac
Number of subjects: 89

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 89
Study: 3549420

Group type: EXPERIMENTAL
Intervention: Trazodone (100-150 mg/day)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: COMPARATOR
Intervention: Trazodone and Placebo
Number of subjects: 29
Study: 31610409

Group type: EXPERIMENTAL
Intervention: Normal sleep (8.5 hours)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Restricted sleep (4.5 hours)
Number of subjects: 14
Study: 29987576

Group type: EXPERIMENTAL
Intervention: sGFP(S65T) gene expression in Pd
Number of subjects: 0
Study: 29939697

Group type: EXPERIMENTAL
Intervention: Induced acute mild arterial hypertension
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no induced hypertension)
Number of subjects: 0
Study: 25450369

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Passive smoking
Number of subjects: 20
Study: 22185623

Group type: EXPERIMENTAL
Intervention: Maternal Sound Stimulation (MSS)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Routine Hospital Sounds (RHS)
Number of subjects: 14
Study: 20552569

Group type: EXPERIMENTAL
Intervention: Direct-likelihood analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complete case analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single imputation techniques (two analyses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pattern-mixture models
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 0
Study: 18821646

Group type: EXPERIMENTAL
Intervention: Exercise plus activity strategy training (Ex + AST)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Exercise plus health education (Ex + Ed)
Number of subjects: 54
Study: 15683356

Group type: EXPERIMENTAL
Intervention: Aged care nurse intervention
Number of subjects: 224

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 224
Study: 12111446

Group type: EXPERIMENTAL
Intervention: Cerebrolysin (Cere), 30 mL injected intravenously, five days per week for four weeks
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Cerebrolysin (Cere)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study: 9923490

Group type: EXPERIMENTAL
Intervention: Sclerokeratoplasty
Number of subjects: 20

Group type: COMPARATOR
Intervention: Total penetrating keratoplasty
Number of subjects: 20
Study: 7589029

Group type: EXPERIMENTAL
Intervention: mizolastine 10 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: cetirizine 10 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: ethanol
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 2012082

Group type: COMPARATOR
Intervention: 5 mg aerosol pentamidine biweekly
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: 60 mg aerosol pentamidine biweekly
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: 120 mg aerosol pentamidine biweekly
Number of subjects: 175
Study: 7084029

Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole (TMP/SMX) 6.8/34 mg/kg/d divided into twice daily doses for six months
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (acute treatment only)
Number of subjects: 21
Study: 30324827

Group type: COMPARATOR
Intervention: Exercise Group (EG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laser Group (LG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laser + Exercise Group (LEG)
Number of subjects: 0
Study: 29937161

Group type: EXPERIMENTAL
Intervention: Elective neck dissection (END)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 221
Study: 27693866

Group type: EXPERIMENTAL
Intervention: Current comorbid psychiatric disorders (mood disorders present in 33.6%, anxiety disorders in 29.6%)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Other stimulant use disorder
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Two or more comorbid psychiatric disorders
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: One or more comorbid disorders
Number of subjects: 302
Study: 24398649

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (60,000 IU/week for 8 weeks followed by 60,000 IU/fortnight)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Calcium (elemental calcium 500 mg twice/day)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Dual supplementation (Cholecalciferol and Calcium)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 22568596

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 54

Group type: COMPARATOR
Intervention: Olmesartan
Number of subjects: 54
Study: 19710188

Group type: EXPERIMENTAL
Intervention: S‐(‐)[2‐13C]equol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: R‐(+)[2‐13C]equol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Racemic (+/‐)[2‐13C]equol
Number of subjects: 12
Study: 17313263

Group type: EXPERIMENTAL
Intervention: Creatine, amino acids, and protein drink (TEST)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Carbohydrate placebo (PLAC)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both TEST and PLAC
Number of subjects: 51
Study: 15172106

Group type: EXPERIMENTAL
Intervention: Pulsed Magnetic Field (MF) exposure for 30 minutes
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sham exposure for 30 minutes
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Pulsed Magnetic Field (MF) exposure
Number of subjects: 70
Study: 11270805

Group type: EXPERIMENTAL
Intervention: amoxicillin/clavulanic acid Solutab tablet (500/125)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: amoxicillin/clavulanic acid Solutab tablet (500/125) after excluding outliers
Number of subjects: 48

Group type: COMPARATOR
Intervention: Augmentan film‐coated tablet (reference)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: amoxicillin/clavulanic acid Solutab tablet (intact or dispersed)
Number of subjects: 48
Study: 9601680

Group type: EXPERIMENTAL
Intervention: Neuronal activity in the visual cortex observed approximately 100-200 ms from stimulus onset.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neuronal activity in the inferior parietal lobe observed after 200 ms.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Premotor activity started later than the inferior parietal lobe activity.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Activity in primary motor and/or motosensory areas observed in some subjects.
Number of subjects: 0
Study: 7977274

Group type: EXPERIMENTAL
Intervention: High levels of dehydroepiandrosterone sulfate (DHEAS)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Control group (matched controls)
Number of subjects: 338
Study: 2693503

Group type: EXPERIMENTAL
Intervention: Group O-600 (600 mg orally R every 8 hours for 48 hours followed by 200 mg every 8 hours for 72 hours, total dose 5.4 g)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Group O-800 (800 mg orally R every 8 hours for 24 hours followed by 400 mg every 12 hours for 96 hours, total dose 4.1 g)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Group A-40 (aerosolized R 40 mg/ml for 6 hours every 12 hours for 96 hours, average delivered dose 6.2 g)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Group A-60 (aerosolized R 60 mg/ml for 2 hours every 8 hours for 96 hours, average delivered dose 4.6 g)
Number of subjects: 16
Study: 802071

Group type: COMPARATOR
Intervention: Hydralazine alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pindolol (Viskén) combined with hydralazine
Number of subjects: 30
Study: 31594904

Group type: EXPERIMENTAL
Intervention: Standard condition of test administration (assumed to activate negative ageing stereotypes)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Reduced-threat instruction condition (designed to alleviate anxiety from stereotypes)
Number of subjects: 260
Study: 27825592

Group type: EXPERIMENTAL
Intervention: Foot orthoses
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Flat insoles
Number of subjects: 18
Study: 26529159

Group type: EXPERIMENTAL
Intervention: efavirenz-based therapy
Number of subjects: 300

Group type: COMPARATOR
Intervention: ritonavir-boosted lopinavir-based therapy
Number of subjects: 300
Study: 23622123

Group type: EXPERIMENTAL
Intervention: Online multi-component psychoeducational intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-intervention semi-structured interview with 20% of participants
Number of subjects: 0
Study: 21809439

Group type: EXPERIMENTAL
Intervention: Dark roast coffee (NMP: 785 μmol/L, CGA: 523 μmol/L)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dark roast coffee
Number of subjects: 30

Group type: COMPARATOR
Intervention: Light roast coffee (CGA: 4538 μmol/L, NMP: 56 μmol/L)
Number of subjects: 30
Study: 18486785

Group type: EXPERIMENTAL
Intervention: Transplantation to surgically created sockets
Number of subjects: 62

Group type: COMPARATOR
Intervention: Transplantation to fresh extraction sites (Control)
Number of subjects: 62
Study: 16813473

Group type: EXPERIMENTAL
Intervention: Multimodal exercise program (50 minutes, 3 times a week for 12 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Multimodal exercise program
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no exercise program)
Number of subjects: 30
Study: 14593691

Group type: EXPERIMENTAL
Intervention: Immediate multi-family psychoeducation groups (MFPG) plus treatment as usual
Number of subjects: 35

Group type: COMPARATOR
Intervention: 6-month wait-list condition plus treatment as usual
Number of subjects: 35
Study: 11069436

Group type: EXPERIMENTAL
Intervention: Drug epidemiology studies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized controlled trial (RCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New-users of the drug
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drug epidemiology
Number of subjects: 0